Gilead Sciences (GILD) : Nippon Life Global Investors Americas reduced its stake in Gilead Sciences by 6.53% during the most recent quarter end. The investment management company now holds a total of 208,726 shares of Gilead Sciences which is valued at $16,608,328 after selling 14,580 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on Aug 9, 2016.Gilead Sciences makes up approximately 1.52% of Nippon Life Global Investors Americas’s portfolio.
Other Hedge Funds, Including , Muhlenkamp Co Inc reduced its stake in GILD by selling 990 shares or 0.45% in the most recent quarter. The Hedge Fund company now holds 217,000 shares of GILD which is valued at $17,303,580. Gilead Sciences makes up approx 6.49% of Muhlenkamp Co Inc’s portfolio.Gerstein Fisher reduced its stake in GILD by selling 1,259 shares or 2.18% in the most recent quarter. The Hedge Fund company now holds 56,486 shares of GILD which is valued at $4,494,591. Gilead Sciences makes up approx 0.57% of Gerstein Fisher’s portfolio.Nelson Van Denburg Campbell Wealth Management Group boosted its stake in GILD in the latest quarter, The investment management firm added 1,192 additional shares and now holds a total of 14,523 shares of Gilead Sciences which is valued at $1,167,794. Gilead Sciences makes up approx 0.48% of Nelson Van Denburg Campbell Wealth Management Group’s portfolio.Oak Ridge Investments reduced its stake in GILD by selling 128,845 shares or 52.72% in the most recent quarter. The Hedge Fund company now holds 115,573 shares of GILD which is valued at $9,293,225. Gilead Sciences makes up approx 0.22% of Oak Ridge Investments’s portfolio.Alps Advisors Inc boosted its stake in GILD in the latest quarter, The investment management firm added 2,661 additional shares and now holds a total of 7,432 shares of Gilead Sciences which is valued at $607,863. Gilead Sciences makes up approx 0.01% of Alps Advisors Inc’s portfolio.
Gilead Sciences opened for trading at $79.46 and hit $80.87 on the upside on Wednesday, eventually ending the session at $80.7, with a gain of 1.83% or 1.45 points. The heightened volatility saw the trading volume jump to 1,05,83,799 shares. Company has a market cap of $106,496 M.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.